25 research outputs found
Distribution of systolic and diastolic blood pressure at baseline.
<p>The distribution of SBP and DBP are presented for the total population and stratified by ESA use. The total percentage of patients within the blood pressure target (DBP: 80 mmHg and SBP: 130 mmHg) are depicted in the histogram. Abbreviations: ESA = Erythropoiesis-Stimulating Agent, SBP = Systolic Blood Pressure, DBP = Diastolic Blood Pressure.</p
Difference in antihypertensive drugs and BP in patients with and without ESA.
<p>Values are presented as mean difference in number of antihypertensive drugs or difference in blood pressure (with 95% Confidence Interval).</p><p><sup>1</sup> Adjusted for age and sex.</p><p><sup>2</sup> Adjusted for age, sex, BMI, Diabetes Mellitus, Cardiovascular disease, eGFR.</p><p>Abbreviations: ESA = Erythropoiesis-Stimulating Agent, SBP = Systolic Blood Pressure, DBP = Diastolic Blood pressure, ref = Reference, BMI = Body Mass Index, eGFR = estimated Glomerular Filtration Rate.</p
Characteristics of patients with and without ESA at the start of pre-dialysis care.
<p>Values are presented as mean (standard deviation) or percentage.</p><p>Abbreviations: ESA = Erythropoiesis-Stimulating Agent, BMI = Body Mass Index, eGFR = estimated Glomerular Filtration Rate.</p
Time course of hepato-splanchnic hemodynamics.
<p>Time course of splanchnic vascular resistance index (<i>RI</i>) (top panel) and hepato-splanchnic perfusion index (<i>QI</i>) (bottom panel) measured at times <i>t</i><sub>1</sub> through <i>t</i><sub>4</sub> during dialysis in diabetic (red symbols) and non-diabetic (green symbols) subjects. Symbols represent average values ± standard deviations of duplicate measurements obtained in treatments separated by one week. For clarity, symbols for diabetics and non-diabetics are placed with a small left or right offset from the actual measuring times.</p
Scheme of hepato-splanchinc contribution for hemodynamic stability.
<p>Splanchnic vasoconstriction reduces arterial inflow (black arrows) thereby lowering downstream distending pressures and mobilizing blood volume (white arrows) sequestered in the compliant splanchnic vasculature. At the same time reduced portal vein flow draining form splanchnic vascular beds (purple) causes a compensatory increase (red arrow) in the separate hepatic arterial blood flow (red) because of compensatory vasodilation in Mall´s space.</p
Hepato-splanchnic perfusion and resistance.
<p>Splanchnic perfusion index (<i>QI</i>) as function of hepato-splanchnic resistance index (<i>RI</i>) (top panel) and hepato-splachnic vascular conductance (bottom panel), respectively, during hemodialysis, in diabetic (red symbols) and non-diabetic (green symbols) subjects. Broken lines indicate the best fit of <i>QI</i> to <i>RI</i> (top panel, <i>y</i> = 6.71/<i>x</i>, <i>r</i><sup>2</sup> = 0.77) and 1/<i>RI</i> (bottom panel, <i>y</i> = 0.02+6.54<i>x</i>, <i>r</i><sup>2</sup> = 0.77), respectively.</p
Characteristics of the overall population, and of ADPKD and IgA Nephropathy patients separately.
<p>Characteristics of the overall population, and of ADPKD and IgA Nephropathy patients separately.</p
Associations of plasma copeptin concentration with urine albumin to creatinine ratio in ADPKD (solid line) and IgA Nephropathy (IgAN, dashed line) patients at maximal urine concentration.
<p>Associations of plasma copeptin concentration with urine albumin to creatinine ratio in ADPKD (solid line) and IgA Nephropathy (IgAN, dashed line) patients at maximal urine concentration.</p
Measurements in plasma at baseline (5 p.m.) and at maximal urine concentration during a standard prolonged water deprivation test.
<p>Measurements in plasma at baseline (5 p.m.) and at maximal urine concentration during a standard prolonged water deprivation test.</p
Associations of maximal urine osmolality with baseline urine-to-plasma (U/P) urea ratio in ADPKD patients (solid line) and IgA Nephropathy patients (IgAN, dashed line).
<p>Associations of maximal urine osmolality with baseline urine-to-plasma (U/P) urea ratio in ADPKD patients (solid line) and IgA Nephropathy patients (IgAN, dashed line).</p